STANFORD UNIVERSITY
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1885-11-11
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.stanford.edu
Clinical Trials
2.0k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1633 trials with phase data)• Click on a phase to view related trials
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
- Conditions
- MedulloblastomaCentral Nervous System Embryonal TumorRefractory MedulloblastomaRecurrent MedulloblastomaPediatric Brain Tumor
- Interventions
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 18
- Registration Number
- NCT07087002
- Locations
- 🇺🇸
Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
Efficacy of Cervical Sympathetic Blocks for PTSD
- Conditions
- PTSD
- Interventions
- Procedure: Cervical sympathetic nerve blockProcedure: Subcutaneous sham injectionDrug: Normal Saline
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 20
- Registration Number
- NCT07087015
Evaluation of Tretinoin Cream on the Integrity of Aged Forearm Skin
- Conditions
- Skin TearSolar PurpuraDermatoporosis
- Interventions
- Drug: Tretinoin 0.1% creamDrug: Bland cream (non-drug)
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 30
- Registration Number
- NCT07084116
- Locations
- 🇺🇸
Palo Alto VA Medical Center, Palo Alto, California, United States
Developing a Digital Aid to Improve ICD Decisions
- Conditions
- Heart Failure and Reduced Ejection Fraction
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 120
- Registration Number
- NCT07084142
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Eastern Carolina University, Greenville, North Carolina, United States
Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome
- Conditions
- Idiopathic HypersomniaPOTS - Postural Orthostatic Tachycardia Syndrome
- Interventions
- Drug: Low sodium oxybate (LXB)Drug: Placebo
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 25
- Registration Number
- NCT07077278
- Prev
- 1
- 2
- 3
- 4
- 5
- 406
- Next
News
Dispatch Bio Emerges with $216M to Develop Universal Solid Tumor Immunotherapy
Dispatch Bio, a new biotech company formed through collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy, has raised $216 million to develop a universal solid tumor treatment approach.
Stanford Researchers Develop Radiation-Free Stem Cell Transplant Protocol for Fanconi Anemia Patients
Stanford Medicine researchers successfully conducted stem cell transplants in three Fanconi anemia patients using the anti-CD117 antibody briquilimab, eliminating the need for toxic radiation or busulfan chemotherapy.
FDA Appoints Biotech Veteran George Tidmarsh to Lead Drug Regulation Center Amid Agency Restructuring
The FDA has appointed Dr. George Tidmarsh, a former pharmaceutical executive and cancer specialist, to direct the Center for Drug Evaluation and Research, the agency's largest division responsible for reviewing drug safety and effectiveness.
Fifty1 AI Labs Completes Landmark Phase III REVIVE Trial for Long COVID Treatment
Fifty1 AI Labs successfully completed the REVIVE Adaptive Platform Trial, the largest and most rigorous Long COVID study to date, enrolling over 600 participants across multiple global sites.
Ashvattha Therapeutics Unveils Novel Nanomedicine Radiotracers for Neuroinflammation and Cancer Imaging at SNMMI 2025
Ashvattha Therapeutics will present data on two breakthrough nanomedicine radiotracers at the SNMMI Annual Meeting, demonstrating selective targeting capabilities in neuroinflammation and cancer.
Fujirebio Partners with Stanford Medicine to Advance Ultrasensitive Infectious Disease Diagnostics
Fujirebio has announced a strategic collaboration with Stanford Medicine to accelerate research and innovation in infectious disease testing using ultrasensitive immunoassays.
Stanford Researchers Develop Milli-Spinner Technology That Doubles Blood Clot Removal Effectiveness
Stanford University researchers have developed a breakthrough milli-spinner thrombectomy technology that shrinks blood clots to just 5% of their original volume through a unique rotating mechanism.
FDA Approves First Drug-Free Wearable Device for Pediatric Nasal Congestion Treatment
The FDA has approved an expanded pediatric indication for the SONU Band, making it the first FDA-approved, drug-free solution for nasal congestion and allergies in children aged 12 years and older.
Continuity Biosciences Acquires Focal Medical to Advance Iontophoresis-Based Pancreatic Cancer Therapy
Continuity Biosciences has acquired Focal Medical, a North Carolina-based company developing site-specific chemotherapy using iontophoresis technology for pancreatic cancer treatment.
Matter Neuroscience Partners with Stanford Medicine to Test Novel fMRI-Guided Depression Therapy
Matter Neuroscience has announced a collaboration with Stanford Medicine to conduct a controlled, multi-arm study enrolling at least 210 depressed patients using real-time 7T fMRI neurofeedback combined with the Matter protocol.